The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study
Study Details
Study Description
Brief Summary
In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
This is a multicenter, prospective, open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Single /arm All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days. |
Drug: Lifitegrast 5% Ophthalmic Solution
Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
|
Outcome Measures
Primary Outcome Measures
- Change in corneal higher order aberrations [After 7, 14, and 28 days of treatment.]
Change in corneal higher order aberrations after 7, 14, and 28 days of treatment.
Secondary Outcome Measures
- Change in OSI after 7, 14, and 28 days of treatment. [After 7, 14, and 28 days of treatment.]
Change in OSI after 7, 14, and 28 days of treatment.
Other Outcome Measures
- Change in best corrected visual acuity after 7, 14, and 28 days of treatment. [After 7, 14, and 28 days of treatment.]
Change in best corrected visual acuity after 7, 14, and 28 days of treatment.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Central or inferior corneal fluorescein staining defined by the Oxford Scale
-
Reduced tear break up time (TBUT) ≤ 10 seconds.
-
Able to comprehend and sign a statement of informed consent.
-
Willing and able to complete all required postoperative visits.
Exclusion Criteria:
-
Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgical procedure performed in the study eye within the last 3 months or at any time that in the investigator's clinical judgment if it would interfere with the outcome measures of this study.
-
Clinically significant ocular trauma.
-
Active ocular Herpes simplex or Herpes Zoster infection
-
Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) that is active, at the discretion of the investigator.
-
Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye), at the discretion of the investigator.
-
Active, systemic or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the questions in the survey and examination findings, in the opinion of the investigator.
-
Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis that would interfere with study findings, in the opinion of the investigator.
-
Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
-
Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis) that would interfere with study findings, in the opinion of the investigator.
-
Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
-
Patients who are under age 18, pregnant or breastfeeding, or who may become pregnant during participation in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Harvard Eye Associates | Laguna Hills | California | United States | 92653 |
| 2 | Bowden Eye & Associates | Jacksonville | Florida | United States | 32256 |
| 3 | Cleveland Eye Clinic | Brecksville | Ohio | United States | 44141 |
Sponsors and Collaborators
- Research Insight LLC
Investigators
- Principal Investigator: John Hovanesian, MD, Research Insight LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CLIF606A1US08T